Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Oral

1442 - NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial

    Primary Author / Presenter(s)

  • MF

    Moritz Fürstenau, MD

    Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne
    Cologne, Germany

    • Co-Author(s)

  • AS

    Anke Schilhabel, PhD

    University of Schleswig-Holstein, Campus Kiel
    Kiel, Schleswig-Holstein, Germany

  • CZ

    Can Zhang

    Statistician
    University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group
    Cologne, Nordrhein-Westfalen, Germany

  • SR

    Sandra Robrecht

    Faculty of Medicine and University Hospital Cologne
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Cologne, Nordrhein-Westfalen, Germany

  • Jv

    Julia v. Tresckow

    Department for Hematology, Oncology and Palliative Care, Catholic Clinic Bochum, Ruhr Univer-sity Bochum, Germany
    Bochum, Nordrhein-Westfalen, Germany

  • MG

    Michael Gregor, MD

    Senior consultant
    Department of Hematology, Luzerner Kantonsspital
    Lucerne, Luzern, Switzerland

  • PT

    Patrick Thornton, MD

    Cancer Clinical Trials Unit, Beaumont Hospital
    Dublin, Ireland

  • PS

    Philip Staber, MD, PhD

    Department of Medicine I, Division of Hematology and Hemostaseology, Medical University
    Vienna, Wien, Austria

  • Tamar Tadmor, MD

    Associate Professor, Head of Hematology Unit
    Bnai Zion Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine
    Haifa, Israel

  • VL

    Vesa Lindström, MD

    Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki
    Helsinki, Uusimaa, Finland

  • GJ

    Gunnar Juliusson, MD, PhD

    Lund University Cancer Center
    Lund, Skane Lan, Sweden

  • AJ

    Ann Janssens, MD

    Department of Hematology Campus Gasthuisberg, University Hospital, Leuven, Belgium
    Leuven, Vlaams-Brabant, Belgium

  • ML

    Mark-David Levin, MD

    Department of Internal Medicine, Albert Schweitzer Hospital
    Dordrecht, Zuid-Holland, Netherlands

  • Cd

    Caspar da Cunha-Bang, MD, PhD

    Rigshospitalet, Copenhagen University Hospital, Department of Hematology
    Copenhagen, Hovedstaden, Denmark

  • CS

    Christof Schneider, MD

    MD
    Division of CLL, Department of Internal Medicine III, University Hospital Ulm
    Ulm, Baden-Wurttemberg, Germany

  • Florian Simon

    Faculty of Medicine and University Hospital Cologne
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Cologne, Nordrhein-Westfalen, Germany

  • AF

    Anna-Maria Fink

    Faculty of Medicine and University Hospital Cologne
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Cologne, Nordrhein-Westfalen, Germany

  • Kirsten Fischer

    Faculty of Medicine and University Hospital Cologne
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne and University of Cologne
    Cologne, Nordrhein-Westfalen, Germany

  • EH

    Emily Holmes, PhD

    German CLL Study Group
    Köln, Nordrhein-Westfalen, Germany

  • KK

    Karl-Anton Anton Kreuzer, MD

    Consultant
    University Hospital Cologne
    Köln, Nordrhein-Westfalen, Germany

  • MB

    Monika Brüggemann, MD, PhD

    University of Schleswig-Holstein, Campus Kiel
    Kiel, Schleswig-Holstein, Germany

  • Eugen Tausch, MD

    Treating Physician and Research Fellow
    Division of CLL, Department of Internal Medicine III, University Hospital Ulm
    Ulm, Germany

  • Stephan Stilgenbauer, MD

    Professor of Medicine, Medical Director
    Division of CLL, Internal Medicine III, Ulm University
    Ulm, Baden-Wurttemberg, Germany

  • Michael Hallek, MD, PhD

    Principal Investigator, Director of Department I of Internal Medicine
    German CLL Study Group, University Hospital of Cologne
    Cologne, Germany

  • Carsten U. Niemann, MD, PhD

    Associate Professor
    Rigshospitalet, Copenhagen University Hospital
    Copenhagen, Hovedstaden, Denmark

  • Arnon P. Kater, MD, PhD

    Vice Chair, Hematologist & Principal Scientist
    Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, and HOVON
    Amsterdam, Noord-Holland, Netherlands

  • MR

    Matthias Ritgen, MD

    University of Schleswig-Holstein, Campus Kiel
    Kiel, Schleswig-Holstein, Germany

  • Barbara Eichhorst, MD

    Associate Professor, Consultant Hematologist
    Department I of Internal Medicine, University Hospital of Cologne
    Cologne, Germany